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Abstract. In areas where visceral leishmaniasis is anthroponotic, asymptomatically infected patients may play a role in
transmission. Additionally, the number of asymptomatic patients in a disease-endemic area will also provide information
on transmission dynamics. Libo Kemkem and Fogera districts (Amhara State, Ethiopia) are now considered newly
established areas to which visceral leishmaniasis is endemic. In selected villages in these districts, we conducted a study
to assess the usefulness of different approaches to estimate the asymptomatic infection rate. Of 605 participants, the rK39
immunochromatographic test was able to detect asymptomatic infection in 1.5% (9 of 605), direct agglutination test in
5.3% (32 of 605), and leishmanin skin test in 5.6% (33 of 589); the combined use of serologic methods and leishmanin skin
test enabled detecting asymptomatic infection in 10.1% (61 of 605). We conclude that the best option to detect asymp-
tomatic infection in this new visceral leishmaniasis–endemic focus is the combined use of the direct agglutination test and
the leishmanin skin test.
INTRODUCTION
Visceral leishmaniasis (VL) is a vector-borne disease caused
by members of the Leishmania (Leishmania) donovani
complex. It is endemic to 65 countries and, among them,
Bangladesh, India, Nepal, Brazil, Sudan, and Ethiopia account
for approximately 90% of the cases. The estimated annual
incidence is 500,000 clinical cases with 59,000 associated
deaths.1,2 Poor populations are particularly affected by VL,
which is considered as one of the most neglected diseases.3 In
addition, VL is currently spreading and re-emerging in differ-
ent areas of the world with increasing public health concern.4
Visceral leishmaniasis is fatal if left untreated, and even with
treatment the case fatality rate ranges from 4% to 10%.5,6 In
stable disease-endemic areas, clinical disease appears only in a
fraction of those infected, and another fraction will not develop
the disease and remain asymptomatic.7 The prevalence of
asymptomatic infection is different between and within differ-
ent disease-endemic countries, and the number of asymptom-
atic infections usually exceeds the number of symptomatic
infections, although this ratio can vary from 0.4:1 to 50:1.2
Visualization of parasite amastigotes by microscopic exam-
ination of bone marrow, spleen, or lymph node aspirates has
been the gold standard method of VL diagnosis for many
years. However, because this procedure is based on invasive
sampling, its use for asymptomatic infection surveillance is
not justified. In addition, in poor, remote, disease-endemic
areas, the expertise and facilities required for these proce-
dures may not be present. Thus, procedures based on less
invasive sampling, such as serologic analysis or leishmanin
skin test (LST) seem to be more suitable for this purpose.
Although detection of antibodies against Leishmania
does not discriminate between current or past infection,
serologic methods have been used to assess asymptomatic
infection in different VL-endemic areas. These methods
have been based on the direct agglutination test (DAT),
rK39-immunochromatographic test (rK39-ICT), enzyme-
linked immunosorbent assay, indirect immunofluorescent
antibody test, or Western blot.8–12
The LST is a useful method for detecting cell-mediated
immunity against Leishmania. Results for this test become
positive after subclinical infection and, in this case, persist
much longer than antibodies against Leishmania. The LST
results also becomes positive within weeks-months after suc-
cessful therapy against VL, indicating a healing or protective
response.13,14 This makes the LST a valuable tool in detecting
exposure to Leishmania parasites in epidemiologic surveys,
and its usefulness to detect asymptomatic infection has been
shown by different authors in different disease-endemic
areas.11,15,16 In general, the LST would detect a higher propor-
tion of asymptomatic infection than serologic analysis. How-
ever, given that serologic analysis and LST are based on
different types of immune responses, in the absence of a gold
standard, the combination of these two approaches would give
a more realistic picture of the asymptomatic infection rate in a
given disease-endemic area.17,18
In areas where VL transmission is anthroponotic, asymp-
tomatic persons might play a role as reservoirs, and even in
areas where VL is zoonotic it is speculated that these persons
could also contribute to transmission.7,19 Thus, assessment of
the prevalence and distribution of asymptomatic cases would
contribute to a better understanding of VL transmission and
help in developing control efforts.
In Ethiopia, VL is an endemic disease of increasing public
health concern. It is estimated that 30% of VL patients in
Ethiopia are malnourished and co-infection with human immu-
nodeficiency virus (HIV) affects 40% in the northwestern
region of this country, and these conditions are known to facil-
itate the spread of VL.20,21 In addition to the classical foci in
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the northwestern region along the border with Sudan (Humera
and Metema) and those in the southern region (Lake Abaya
region, Omo River, and Aba Roba plains), the disease has
recently spread to previously non-endemic areas, such as Libo
Kemkem and Fogera (highland districts in Amhara State)
where a VL outbreak occurred in 2004–2005.15 Thus, VL is
currently a priority in the public health agenda of the Amhara
State Health Bureau, and there is a need to generate epidemi-
ologic data on VL in Amhara State.
To support VL control, facilities for treatment, mobile teams
for surveillance, community mobilization, and active case
detection strategies have been established. To contribute to this
initiative the UBS-Optimus Foundation supported the project
entitled Visceral Leishmaniasis and Malnutrition in Amhara
State, Ethiopia, which among its specific objectives aimed
to characterize nutritional, immunologic, and parasitologic
aspects in the child population from this area, and it is within
the framework of this project that we have explored the use-
fulness of rK39-ICT, DAT, and LST to detect asymptomatic
Leishmania infection in children from different sub-districts of
Libo Kemkem and Fogera. Furthermore, detection of asymp-
tomatic infection in children will provide information about
the status of VL transmission in this highland focus. In addition,
this information will contribute to assessment of the magnitude
of asymptomatic infection, which can help in early detection
and treatment, thus contributing to decreased transmission,
morbidity, and mortality. The information obtained can also be
useful in a scenario in which HIV spreads to Leishmania-
endemic areas, and help to foresee new VL cases among asymp-
tomatic persons as a consequence of a reactivation of previous
Leishmania infections after acquired HIV.22
MATERIALS AND METHODS
Study site. The study was conducted during May–July 2009
in the districts (weredas) of Libo Kemkem and Fogera,
Amhara State, Ethiopia (Figures 1 and 2). These are adjacent
districts most affected by the outbreak of VL that occurred in
2004–2005.15 According to the 2009 census, the population was
198,374 (males = 100,951 and females = 198,374) and 226,595
(males = 115,693 and females = 110,902) for Libo Kemkem and
Fogera, respectively. The districts are located in a black cotton
clay soil flat plain (1800–2000 meters above sea level). Human
activities related to intensive cultivation of teff, maize, beans,
oilseeds, rice, and cotton have reduced the natural vegetation
to scattered clumps of acacia trees. Most of the area is flooded
during the rainy season (July–September) and dried up during
the dry season (November–May), resulting in deep cracks in
the soil surface, which could become breeding sites for the
putative vector Phlebotomus orientalis.23,24
Study population. Population sampling was carried out by
using a multi-staged cluster survey. Primary sampling units
were sub-districts (kebeles) with high incidence of VL
according to the 2008 register of the Addis Zemen VL Treat-
ment Center: Agita, Bura, and Yifag from Libo Kemkem
district and Dibasifatra and Rib Gebriel from Fogera district.
Secondary sampling units were randomly selected villages
(gotts) in each of the selected sub-districts. Tertiary sampling
units were randomly selected households in each of the villages.
All children with a reported age between 4 and 15 years living
in the household at the time of the survey were eligible for
the study, as long as they were asymptomatic and had no
history of VL.
Figure 1. Location of the study area in Ethiopia.
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Data collection. Information on age, sex, residence, and
clinical assessment was obtained for all participants by trained
medical personnel (nurses and health officers) by using
pretested questionnaires and protocols.
Asymptomatic case definition.Asymptomatic persons were
those who had a positive result in the rK39-ICT, DAT, or
LST, and the absence of VL signs and symptoms (fever for
> 2 weeks, in combination with either enlargement of spleen
and/or liver, or weight loss).
Sample collection and storage. Peripheral blood was col-
lected in tubes containing Na2-EDTA (Sigma, St. Louis,
MO) and immediately one drop was used for the rK39-ICT
and two drops were spotted onto Whatman 3MM filter paper
(Whatman International Ltd., Maidstone, United Kingdom).
Filter papers were left to air dry and placed individually in
sealed plastic bags. The plastic bags containing filter papers
were kept in a chilled icebox and sent on the same day to the
Amhara State Regional Laboratory, where they were stored
at 4°C for further DAT analysis.
Ethical considerations. The study was approved by the eth-
ical review boards of Instituto de Salud Carlos III, the Armauer
Hansen Research Institute, and the Ethiopian National Ethical
Review Committee. Support letters were obtained from the
Amhara State and health bureaus in different districts. Parents/
guardians gave written informed consent before enrollment of
their children in the study. For children > 11 years of age,
verbal assents were also obtained in addition to the consent
of their parents/guardians.
Detection of antibodies against Leishmania. The rK39-ICT
(Kalazar DetectÒ Rapid Test; InBios International Inc., Seattle,
WA) was performed by using 1 drop of blood and 3 drops of
chasing buffer according to the manufacturer’s instructions.
The DAT with freeze-dried antigen (ITMA-DAT/VL; Prince
Leopold Institute of Tropical Medicine, Antwerp, Belgium)
Figure 2. Location of the sub-districts in which the study was conducted (gray background) in Ethiopia.
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was performed by using the screening method according to the
manufacturer’s protocol. Blood samples with a titer ³ 1:3,200
were considered positive.
Leishmanin skin test. The LST was performed by using
L. major antigen (Leishmanin batch 123-2; Pasteur Institute,
Tehran, Iran). One hundred microliters of the antigen were
intradermally inoculated on the volar surface of the forearm
with a 1-mL sterile syringe and disposable needle. The test
was read 48 hours later by using the ballpoint pen method. An
induration with an average of two perpendiculars ³ 5 mm was
considered positive.
Data analysis. Infection prevalence was calculated by using
rK39-ICT, DAT, and LST results. The differences in infection
prevalence between age group, sex, and location were com-
pared by using Fisher’s exact and chi-square tests. A P value
< 0.05 was considered statistically significant. Data analysis was
performed by using SPSS version 16.0 (SPSS Inc., Chicago, IL)
and STATA version 10 (StataCorp LP, College Station, TX).
RESULTS
A total of 639 children were screened; one of them was
an active case of malaria, three had an active VL episode, and
28 reported having VL in the past. For two other children, their
previous VL history was unknown. These findings resulted in
605 asymptomatic children without previous VL eligible for
analyses. The active malaria and VL cases were referred to
the Addis Zemen Health Center for further clinical examina-
tion and treatment.
Of the 605 participants, 309 were boys (51.1%) and 296
were girls (48.9%). The boy:girl ratio was approximately 1:1
in the two districts studied. The mean ± SD age of the partic-
ipants was 8.8 ± 0.13 years (there was no difference between
the sexes). The children were grouped according to their age
into three groups: group 1 (< 5 years of age) consisted of 77 of
605 (12.7%) children, group 2 (5–9 years of age) consisted of
295 (48.8%) of 605 children, and group 3 (10–15 years of age)
consisted of 233 (38.5%) of 605 children.
Antibodies against Leishmania were detected in 9 (1.5%)
of 605 children by the rK39-ICT and in 32 (5.3%) of 605 by
the DAT. Sixteen (2.6%) of the 605 children initially tested
by LST were lost for analysis. This test showed a positive
result for 33 (5.6%) of 589 children.
Globally, 38 (6.3%) of 605 children were seropositive
(rK39-ICT and/or DAT positive), and 61 (10.1%) of 605 chil-
dren were considered infected (positive by rK39-ICT and/or
DAT and/or LST). For the group of 589 children tested by
using the three methods, we observed that 27 of 37 seroposi-
tive children had a negative LST result, although 23 of 33 LST-
positive children were seronegative. A detailed description
of the performance of these three methods in the group of
589 children is shown in Table 1.
The mean ± SD age of those with asymptomatic infection
was 10.6 ± 3.4 years. Analysis by age group showed a positive
association between asymptomatic infection and age, and
children 10–15 years of age had a higher asymptomatic infec-
tion rate (16.3%; P < 0.0001). This finding was common for all
tests used.
A strong association was also found with regard to sex, with
infection in boys being higher than in girls (13.9% versus
6.1%; P = 0.001). Differences in asymptomatic infection rate
by age and sex are shown in Table 2.
The highest prevalence of asymptomatic infection was
found in the selected villages in Bura (25.0%) and the lowest
prevalence was found in villages in Agita (1.5%).
A detailed description of the results obtained by the three
methods used by sex, age, and location is shown in Table 3.
DISCUSSION
Our study shows the presence of asymptomatic Leishmania
infection among children 4–15 years of age in the districts of
Libo Kemkem and Fogera, in the new VL focus of Amhara
State in northwestern Ethiopia. The observed overall asymp-
tomatic infection rate was 10.1% (61 of 605). This rate was
determined by using a combination of serologic methods,
which detected 38 (6.3%) of 605 seropositive persons and
LST, which detected 33 (5.6%) of 589 seropositive persons.
As proposed initially, the combination of serologic analysis
and LST enabled wider detection of asymptomatic infections.
The discordances observed between serologic analysis and
LST were expected. Both LST and serologic analysis have
been used to assess exposure to Leishmania, irrespective of
disease presentation, and are frequently used in epidemio-
logic studies in Leishmania-endemic areas.9,25,26 Nevertheless,
comparison of LST positivity and seroprevalence rates is com-
plicated by different types of immune response detected by
each test. The LST measures a delayed-type hypersensitivity
reaction to Leishmania and relies on an in vivo cellular
immune response to Leishmania antigens. Seropositivity is
the result of a significant level of Leishmania-specific anti-
bodies in the peripheral blood, which is based on a humoral
immune response. The two differentiated groups of LST-
positive/seronegative and LST-negative/seropositive children
observed in our study are consistent with the lack of an asso-
ciation between LST and serologic results. The LST positivity
appears later after infection and seems to be a sign of protec-
tive immunity against VL. Seropositivity is considered an
Table 1
Performance of the rK39-ICT, DAT, and LST for detection of visceral leishmaniasis in 589 children tested, Ethiopia*
LST




+ – + –
+ 2/589 (0.3) 6/589 (1.0) 2/589 (0.3) 23/589 (3.9) 33/589 (5.6)
– 0/589 (0.0) 23/589 (3.9) 4/589 (0.7) 529/589 (89.8) 556/589 (94.4)
31/589 (5.3) 558/589 (5.3) Total = 589 (100)
*rK39-ICT = rK39-immunochromatographic test; DAT = direct agglutination test; LST = leishmanin skin test.
†Global rK39-ICT positive = 8 (1.4%).
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indicator of more recent infection and has been related to
disease progression.27,28 However, a recent seroepidemiologic
study in Bihar, India, observed low disease conversion rate in
asymptomatic DAT-positive persons.29
Different studies in VL-endemic areas have shown that LST
detects a higher Leishmania infection rate in asymptomatic
persons than serologic analyses.8,11,26,30–32 In contrast, our
study shows that the infection rate obtained by serologic anal-
ysis is similar to that obtained with the LST, 6.3% versus 5.6%
using DAT and rK39-ICT, and 5.3% versus 5.6% using DAT
alone. Given that VL has recently been reported in our study
area and that our study population is children, this finding can
be associated with the longer time needed for development
of a LST-positive response compared with seroconversion. If
we consider that LST-positive conversion is the result of a
repeated exposure to natural infection, this would also explain
why LST positivity is higher in the older age group.
We observed a high discordance between DAT and rK39-
ICT in our study (Table 1). Six persons with a positive rK39-
ICT result were negative by DAT, 29 DAT-positive persons
were negative by rK39-ICT result, and only three persons
had a positive result by both serologic methods. Although
Ritmeijer and others33 and Chappuis and others34 reported a
lower sensitivity of rK39-ICT in Sudan, meta-analysis on the
performance of DAT and rK39-ICT for active VL diagnosis
concluded that both tests have a similar level of sensitivity. In
addition, a recent study in Libo Kemkem that evaluated the
performance of DAT and two rK39-ICT tests indicated that
either approach is suitable for VL diagnosis in this area of
Ethiopia.35 However, our study population was asymptomatic
and higher positivity rates have been reported for DAT ver-
sus rK39-ICT when these methods are used to assess asymp-
tomatic infection in other VL-endemic areas.7 Given that
performance of a serologic test can depend on the stage of
the disease/infection, the lower performance of rK39-ICT can
be explained by its ability to detect antibody response against
only a single antigen (rK39), whereas the DAT relies on
detection of antibodies against a wide range of Leishmania
antigens (whole freeze-dried promastigote).36 Another expla-
nation is based on the nature of the tests. As proposed by Ter
Horst and others, antibodies detected by rK39-ICT could be
less able to react in a rapid reaction than in the overnight
incubation used for DAT.37
Although the DAT has shown better performance in
detecting asymptomatic infections in our study population,
six persons with a positive result for the rK39-ICT result but
a negative result for the DAT merits attention. A possible
explanation for this finding might be the different volumes of
blood tested with each method. Although in our study rK39-
ICT was performed with one drop of blood, the DAT was
performed with a 5-mm disk punched out from a spot of two
drops of blood on a filter paper, which can be considered a
lower amount of blood. In addition, Zijlstra and others
reported that an rK39-based test (in an enzyme-linked immu-
nosorbent assay format) detected asymptomatic infection ear-
lier than the DAT.38
The increase of asymptomatic infection rate with age
was consistent with an endemic focus of VL and a marked
increase in persons > 5–9 years of age. In addition, asymptom-
atic infections in persons < 5 years of age is also consistent
with active transmission, despite the low VL incidence
observed after the outbreak.6
The present study indicates the appropriateness of combin-
ing serologic analysis (DAT) and LST to obtain a consistent
picture of the asymptomatic infection rate in a VL-endemic
area. This work also indicates that after the 2004–2005 VL
outbreak, active transmission is still occurring in the villages
studied and that L. donovani transmission can potentially be
established in highlands (1,800–2,000 meters above sea level)
in Ethiopia, which are commonly considered free of VL.
Our study has also enabled us to select appropriate tools to
be used in different tasks during the UBS-Optimus Foundation
project, such as estimation of infection prevalence, follow-up of
those persons with asymptomatic infections, and further study
Table 3
Asymptomatic infection rates for visceral leishmaniasis detected by three tests and their combination by sex, age, and location, Ethiopia*
Variable
Tests
rK39-ICT, no. (%) DAT, no. (%) LST,† no. (%) Seropositive, no. (%) Infected, no. (%)
Whole population (n = 605) 9 (1.5) 32 (5.3) 33 (5.6) 38 (6.3) 61 (10.1)
Sex
Boys (n = 309) 7 (2.3) 22 (7.1) 23 (7.6) 28 (9.1) 43 (13.9)
Girls (n = 296) 2 (0.7) 10 (3.4) 10 (3.5) 10 (3.4) 18 (6.1)
Age group (years)
< 5 (n = 77) 1 (1.3) 2 (2.6) 1 (1.3) 2 (2.6) 2 (2.6)
5–9 (n = 295) 3 (1.0) 13 (4.4) 8 (2.8) 15 (5.1) 21 (7.1)
10–15 (n = 233) 5 (2.1) 17 (7.3) 24 (10.6) 21 (9.0) 38 (16.3)
Sub-district
Agita (n = 133) 0 (0.0) 2 (1.5) 0 (0.0) 2 (1.5) 2 (1.5)
Bura (n = 140) 3 (2.1) 17 (12.1) 23 (16.5) 18 (12.9) 35 (25.0)
Dibasifatra (n = 133) 5 (3.8) 3 (2.2) 4 (3.1) 7 (5.3) 10 (7.5)
Rib Gebriel (n = 132) 1 (0.7) 7 (5.3) 6 (4.6) 8 (6.1) 11 (8.3)
Yifag (n = 67) 0 (0.0) 3 (4.5) 0 (0.0) 3 (4.5) 3 (4.5)
*rK39-ICT = rK39-immunochromatographic test; DAT = direct agglutination test; LST = leishmanin skin test.
†For 589 children.
Table 2
Rate of asymptomatic infection of visceral leishmaniasis by sex and
age, Ethiopia
Age group (years)
Rate of asymptomatic infection, no. infected/no. tested (%)
Boys Girls Both sexes
< 5 1/34 (2.9) 1/43 (2.3) 2/77 (2.6)
5–9 16/140 (11.4) 5/155 (3.2) 21/295 (7.1)
10–15 26/135 (19.3) 12/98 (12.2) 38/233 (16.3)
Total 43/309 (13.9) 18/296 (6.1) 61/605 (10.1)
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of associations between malnutrition, Leishmania infection,
and active disease. These tools have been locally evaluated
and shown to be applicable under field conditions. They will
enable investigators to conduct epidemiologic surveillance,
thus contributing to ongoing efforts of the Amhara State
Health Bureau to control spread of VL to adjacent areas.
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